Mounjaro Lawsuits: Gastrointestinal Risks & FDA Response
These popular weight-loss and diabetes medications, Mounjaro and Ozempic, are facing intense scrutiny due to a surge in lawsuits alleging underreporting of severe gastrointestinal side effects. This article examines the legal actions, scientific evidence, and regulatory implications surrounding these concerns. Understanding the Lawsuits Numerous lawsuits claim that Eli Lilly (Mounjaro) and Novo Nordisk (Ozempic) inadequately warned patients and healthcare providers about the potential for serious gastrointestinal consequences, including gastroparesis (delayed stomach emptying)....